Title :

Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients

Author(s) :

Mekinian, Arsène [Auteur]
Biard, Lucie [Auteur]
Dagna, Lorenzo [Auteur]
Novikov, Pavel [Auteur]
Salvarani, Carlo [Auteur]
Espitia, Olivier [Auteur]
Sciascia, Savino [Auteur]
Michaud, Martin [Auteur]
Lambert, Marc [Auteur]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Hernández-Rodríguez, José [Auteur]
Schleinitz, Nicolas [Auteur]
Awisat, Abid [Auteur]
Puéchal, Xavier [Auteur]
Aouba, Achille [Auteur]
Munoz Pons, Helene [Auteur]
Smitienko, Ilya [Auteur]
Gaultier, Jean Baptiste [Auteur]
Le Mouel, Edwige [Auteur]
Benhamou, Ygal [Auteur]
Perlat, Antoinette [Auteur]
Jego, Patrick [Auteur]
Goulenok, Tiphaine [Auteur]
Sacre, Karim [Auteur]
Lioger, Bertrand [Auteur]
Hassold, Nolan [Auteur]
Broner, Jonathan [Auteur]
Dufrost, Virginie [Auteur]
Sene, Thomas [Auteur]
Seguier, Julie [Auteur]
Maurier, Francois [Auteur]
Berthier, Sabine [Auteur]
Belot, Alexandre [Auteur]
Frikha, Faten [Auteur]
Denis, Guillaume [Auteur]
Audemard-Verger, Alexandra [Auteur]
Kone Pault, Isabelle [Auteur]
Humbert, Sebastien [Auteur]
Woaye-Hune, Pascal [Auteur]
Tomelleri, Alessandro [Auteur]
Baldissera, Elena [Auteur]
Kuwana, Masataka [Auteur]
Lo Gullo, Alberto [Auteur]
Gaches, Francis [Auteur]
Zeminsky, Pierre [Auteur]
Galli, Elena [Auteur]
Alvarado, Moya [Auteur]
Boiardi, Luigi [Auteur]
Muratore, Francesco [Auteur]
Vautier, Mathieu [Auteur]
Campochiaro, Corrado [Auteur]
Moiseev, Sergey [Auteur]
Cacoub, Patrice [Auteur]
Fain, Olivier [Auteur]
Saadoun, David [Auteur]

Journal title :

Rheumatology

Pages :

1376-1384

Publisher :

Oxford University Press (OUP)

Publication date :

2022-04-01

ISSN :

1462-0324

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Abstract Objective To assess the safety and the efficacy of TNF-α antagonists and tocilizumab in patients with Takayasu arteritis (TAK). Methods A total of 209 patients with TAK [median age 29 years (interquartile range ...
Show more >Abstract Objective To assess the safety and the efficacy of TNF-α antagonists and tocilizumab in patients with Takayasu arteritis (TAK). Methods A total of 209 patients with TAK [median age 29 years (interquartile range 7–62)], 186 (89%) females] were included. They received either TNF-α antagonists [n = 132 (63%) with 172 lines; infliximab (n = 109), adalimumab (n = 45), golimumab (n = 8), certolizumab (n = 6) and etanercept (n = 5)] or tocilizumab [n = 77 (37%) with 121 lines; i.v. and s.c. in 95 and 26 cases, respectively]. Results A complete response at 6 months was evidenced in 101/152 (66%) patients on TNF-α antagonists and 75/107 (70%) patients on tocilizumab. Age ≥30 years [odds ratio 2.09 (95% CI 1.09, 3.99)] was associated with complete response, whereas vascular signs [OR 0.26 (95% CI 0.1, 0.65)], baseline prednisone ≥20 mg/day [OR 0.51 (95% CI 0.28, 0.93)] were negatively associated with the complete response to TNF-α antagonists or tocilizumab. During a median follow-up of 36 months, 103 relapses were noted. Supra-aortic branches and thoracic aorta involvement [HR 2.44 (95% CI 1.06, 5.65) and 3.66 (1.18, 11.4), respectively] and systemic signs at baseline [HR 2.01 (95% CI 1.30, 3.11)] were significantly associated with relapse. The cumulative incidence of treatment discontinuation and relapse were similar in TNF-α antagonists and tocilizumab. Fifty-eight (20%) adverse effects occurred on biologic targeted therapies [37 (21%) on TNF-α antagonists and 21 (17%) on tocilizumab (P = 0.4), respectively]. Conclusion This large multicentre study shows high efficacy of biologic targeted treatments in refractory TAK. Efficacy, relapse and drug retention rate were equivalent with TNF-α antagonists and tocilizumab.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167

Source :

Harvested from HAL